Country for PR: China
Contributor: PR Newswire Asia (China)
Thursday, July 02 2020 - 11:08
CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.
SUZHOU, China, July 2, 2020 /PRNewswire-AsiaNet/ --

CF PharmTech, Inc. ("CF PharmTech") announced today that it has raised US $50M 
in Series F financing following its US $90M Series E financing in January of 
2020, in total, successfully completing an equity investment deal of nearly US 
$140M within six months. The investors participated in the Series F financing 
include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and 
Watson Investment. Its existing investors including Passion Capital and 
Yuanming Capital also participated. CEC Capital served as CF PharmTech's 
exclusive financial advisor for both Series E and F financing. 

Photo - 

There are nearly 300 million people suffering from asthma, chronic obstructive 
pulmonary disease (COPD) or rhinitis in China. The occurrence of these chronic 
diseases continues to rise. The State Council's Opinions on the Implementation 
of Healthy China Actions issued by the State Council in July 2019 defined COPD 
in China as a major chronic disease that seriously affects quality of life, 
along with cancers, cardiovascular disease and diabetes. With this new round of 
funding, CF Pharmtech is more poised than ever to provide respiratory disease 
treatments for China and global market. 

About CF PharmTech:

CF PharmTech is a fully integrated specialty pharmaceutical company dedicated 
to providing affordable and high-quality respiratory drugs globally.  Managed 
by a high caliber team with extensive experience in the industry, the company 
focuses on the development of drugs for the treatment of respiratory diseases 
in its state-of-the-art facilities. Learn more about CF PharmTech, visit  

SOURCE: CF PharmTech, Inc.

Image Attachments Links:


   Caption: CF PharmTech's manufacturing facility